Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 691 to 700 of 2245 total matches.
In Brief: Mechlorethamine Gel (Valchlor) for Cutaneous T-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
daily for up to 1 year. Response rates, based on a composite assessment of index lesion severity, were ...
The FDA has approved a 0.016% gel formulation of the nitrogen mustard mechlorethamine (Valchlor – Actelion) for second-line topical treatment of patients with stage IA or IB mycosis fungoides, the most common type of cutaneous T-cell lymphoma. Topical nitrogen mustard has been used off-label for decades for this indication, usually as a pharmacy-compounded ointment, but no clinical trials evaluating its efficacy and safety have been done. Mechlorethamine is also available in an injectable formulation (Mustargen – Recordati) for the same and other indications.FDA approval of Valchlor was...
Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
by the FDA for PTCL. The
first was the antifolate drug pralatrexate (Folotyn),1
which was followed ...
The FDA has approved belinostat (Beleodaq –
Spectrum), an IV histone deacetylase (HDAC)
inhibitor, for treatment of adults with relapsed or
refractory peripheral T-cell lymphoma (PTCL). It is
the third IV drug approved by the FDA for PTCL. The
first was the antifolate drug pralatrexate (Folotyn),
which was followed by the HDAC inhibitor romidepsin
(Istodax). Vorinostat (Zolinza), an oral HDAC
inhibitor, is FDA-approved for treatment of cutaneous
T-cell lymphoma.
Pomalidomide (Pomalyst) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
on days 1-21 of a 28-day cycle
alone or combined with 40 mg/week of dexamethasone.
Progression-free ...
The FDA has approved pomalidomide (Pomalyst –
Celgene), an oral thalidomide analog, for treatment
of patients with multiple myeloma who have received
at least 2 prior therapies including lenalidomide
(Revlimid) and bortezomib (Velcade) and whose
disease had progressed on or within 60 days of
completion of the last therapy.
Ivermectin Cream (Soolantra) for Rosacea
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015 (Issue 1466)
' tra
The FDA has approved a 1% cream formulation
of the antiparasitic drug ivermectin (Soolantra ...
The FDA has approved a 1% cream formulation
of the antiparasitic drug ivermectin (Soolantra –
Galderma) for topical treatment of inflammatory
lesions of rosacea. Ivermectin is available in the US
in tablets (Stromectol, and generics) for treatment of
onchocerciasis and other worm infestations and as a
0.5% lotion (Sklice) for treatment of head lice.
In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015 (Issue 1466)
, and others).1 Symptomatic bradycardia
was reported following initiation of treatment with
Harvoni ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...
Gardasil 9 - A Broader HPV Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
disease associated with HPV types 6, 11, 16,
and 18,1 and Cervarix prevents disease associated
with HPV ...
The FDA has now approved a recombinant, 9-valent,
human papillomavirus (HPV) vaccine (Gardasil 9 –
Merck) for use in girls and women 9-26 years old and
boys 9-15 years old. The new vaccine is indicated to
prevent diseases associated with infection with HPV
types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which include
genital warts and cervical, vulvar, vaginal, and anal
precancerous lesions and cancer. Two recombinant
HPV vaccines are already available in the US: Gardasil
prevents disease associated with HPV types 6, 11, 16,
and 18, and Cervarix prevents disease associated
with HPV...
OTC Fluticasone Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
(Nasacort Allergy 24HR) was
the first.1 Unlike prescription Flonase, the OTC product
is FDA-approved ...
The nasal spray formulation of the corticosteroid
fluticasone propionate is now available over the
counter (OTC) as Flonase Allergy Relief (GSK) in
the same strength as the prescription product
(Flonase, and generics) for patients ≥4 years old with
seasonal or perennial allergic rhinitis. It is the second
corticosteroid nasal spray to become available OTC;
triamcinolone acetonide (Nasacort Allergy 24HR) was
the first. Unlike prescription Flonase, the OTC product
is FDA-approved for reduction of ocular as well as
nasal symptoms. Brand-name prescription Flonase
has been...
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
usually continues for at least 3 months.1,2
In patients with nonvalvular atrial fibrillation,
dabigatran ...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
Secukinumab (Cosentyx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
associated
with multiple comorbidities.1 Topical preparations,
including corticosteroids and vitamin D ...
Secukinumab (Cosentyx – Novartis), an injectable
human interleukin (IL)-17A antagonist, has been
approved by the FDA for treatment of moderate to
severe plaque psoriasis in adult patients who are
candidates for systemic therapy or phototherapy.
It is the first IL-17 inhibitor to be approved for any
indication in the US.
Spiriva Respimat - An Oral Inhalation Spray for COPD
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
obstructive pulmonary disease (COPD),1 has now also
been approved in an inhalation spray formulation ...
Tiotropium bromide, an inhaled long-acting anticholinergic
available since 2004 as a dry powder inhaler
(Spiriva Handihaler) for once-daily treatment of chronic
obstructive pulmonary disease (COPD), has now also
been approved in an inhalation spray formulation
(Spiriva Respimat – Boehringer Ingelheim). According
to the manufacturer, the Respimat device improves
delivery of tiotropium to the lungs because, unlike with
the Handihaler, it is not dependent on the strength of
the patient’s breath intake.